-
2025-524487-37-00
6
Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MP
-
2025-521712-19-00
5
2026-07-06
Colorectal Cancer
-
2025-523806-34-00
4
2026-07-06
relapsed/refractory Large B-Cell Lymphoma
-
2024-516896-34-00
9
2026-06-17
progressive/relapsed/refractory pediatric low-grade glioma (pLGG)
-
2025-522038-29-00
5
2026-06-16
Locally advanced, unresected (unresectable or medically inoperable or
-
2025-522643-18-00
5
2026-06-16
Stage I NSCLC
-
2025-523005-15-00
9
2026-06-15
Non-Hodgkin Lymphoma
-
2025-523524-53-00
9
2026-06-12
ADVANCED OR METASTATIC RENAL CELL CARCINOMA
-
2025-523630-59-00
9
2026-06-12
colon carcinoma metastases
-
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
-
2025-524316-11-00
5
2026-06-11
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-523521-18-00
5
2026-06-09
Metastatic Colorectal Cancer
-
2024-519326-20-00
4
2026-06-08
Patients with diagnosis of unresectable clinical stage III or IV metas
-
2025-521950-41-00
5
2026-06-05
severe uncontrolled asthma
-
2024-520446-31-00
5
2026-05-27
Participants with overweight or obesity, and type 2 diabetes
-
2025-521911-38-00
7
2026-05-26
Advanced HR+/HER- breast cancer
-
2024-518835-13-00
5
2026-05-19
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-521903-28-00
5
2026-05-06
Adenovirus viremia
-
2025-523230-77-00
4
2026-04-27
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
-
2025-523231-19-00
4
2026-04-27
Cutaneous Squamous Cell Carcinoma
-
2025-520715-13-00
4
2026-04-22
Idiopathic Pulmonary Fibrosis